OncoMatch/Clinical Trials/NCT06972576
Clinical Study of Combined EphA2-targeted CAR-DC and CAR-T Cell Therapy for Non-small Cell Lung Cancer
Is NCT06972576 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies multiple treatments including EphA2-targeted CAR-T Cells and EphA2-targeted CAR-DCs for non-small cell lung cancer.
Treatment: EphA2-targeted CAR-T Cells · EphA2-targeted CAR-DCs — This is an open-label, single-arm clinical study designed to evaluate the safety and preliminary efficacy of EphA2-targeted CAR-DC combined with CAR-T cell therapy in patients with non-small cell lung cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: EPHA2 expression ≥20% by immunohistochemistry (≥20%)
Tumor tissue tested positive for EphA2 expression by immunohistochemistry (≥20%)
Disease stage
Required: Stage IV
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: chemotherapy
patients must have received at least two prior systemic therapies, including but not limited to chemotherapy and immune checkpoint inhibitors
Must have received: immune checkpoint inhibitor
patients must have received at least two prior systemic therapies, including but not limited to chemotherapy and immune checkpoint inhibitors
Must have received: targeted therapy
patients with actionable driver mutations must have failed targeted therapy
Lab requirements
Blood counts
Absolute neutrophil count (ANC) ≥1.5×10^9/L, platelet count ≥75×10^9/L, hemoglobin ≥9 g/dL. No transfusions, G-CSF, thrombopoietin, or erythropoietin allowed within 14 days before blood tests.
Kidney function
Serum creatinine (Cr) ≤1.5×ULN, or if Cr >1.5×ULN, creatinine clearance (CrCl) ≥60 mL/min calculated using the Cockcroft-Gault formula.
Liver function
Total bilirubin (TBIL) <1.5× ULN; AST and ALT <2.5×ULN. For patients with Gilbert's syndrome, TBIL <2×ULN; if liver metastases are present, AST and ALT <5×ULN.
Adequate organ function, including: Adequate hematologic function: Absolute neutrophil count (ANC) ≥1.5×10^9/L, platelet count ≥75×10^9/L, hemoglobin ≥9 g/dL. No transfusions, granulocyte colony-stimulating factor (G-CSF), thrombopoietin, or erythropoietin allowed within 14 days before blood tests. Adequate hepatic function: Total bilirubin (TBIL) <1.5× ULN; AST and ALT <2.5×ULN. For patients with Gilbert's syndrome, TBIL <2×ULN; if liver metastases are present, AST and ALT <5×ULN. Adequate renal function: Serum creatinine (Cr) ≤1.5×ULN, or if Cr >1.5×ULN, creatinine clearance (CrCl) ≥60 mL/min calculated using the Cockcroft-Gault formula. Adequate coagulation function: Prothrombin time (PT) and activated partial thromboplastin time (APTT) <1.5×ULN; international normalized ratio (INR) <1.5 or within the target range if on anticoagulant therapy.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06972576 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received chemotherapy and immune checkpoint inhibitor.
Does this trial require EPHA2?
Yes, EPHA2 expression ≥20% by immunohistochemistry is a required biomarker for enrollment.
What disease stage is eligible?
Stage IV is required (metastatic disease required).
Is there an age limit?
Yes. Patients must be 70 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages